Register Login

Amylyx Pharmaceuticals Inc. (AMLX)

Klee Justin B. 🟡 adjusted position in 138.2K shares (2 derivative) of Amylyx Pharmaceuticals, Inc. (AMLX) at $13.89 ($4.9M) Transaction Date: Jan 15, 2026 | Filing ID: 017056

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 2:20 p.m.

    🔍 Klee Justin B. (Executive)

    Company: Amylyx Pharmaceuticals, Inc. (AMLX)

    Report Date: 2026-01-15

    Transaction Summary:

    • Total transactions: 6
    • Derivative instruments: 2
    • Holdings reported: 0
    • Total shares acquired: 200,000
    • Total shares sold: 338,188

    Detailed Transactions and Holdings:

    • Acquired 197,153 shares of Common Stock at $7.57 per share (Direct)
      Date: 2026-01-15 | Code: M | equity_swap_involved: false | shares_owned_after: 3,514,739.00 | transaction_form_type: 4
    • Sold 136,193 shares of Common Stock at $13.5827 per share (Direct)
      Date: 2026-01-15 | Code: S | equity_swap_involved: false | shares_owned_after: 3,378,546.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Acquired 2,847 shares of Common Stock at $7.57 per share (Direct)
      Date: 2026-01-16 | Code: M | equity_swap_involved: false | shares_owned_after: 3,381,393.00 | transaction_form_type: 4
    • Sold 1,995 shares of Common Stock at $13.8853 per share (Direct)
      Date: 2026-01-16 | Code: S | equity_swap_involved: false | shares_owned_after: 3,379,398.00 | transaction_form_type: 4 | Footnotes: F1, F3
    • Sold 197,153 shares of Stock Option (Right to Buy) at $7.57 per share (Derivative)
      Date: 2026-01-15 | Code: M | Expires: 2026-02-19 | equity_swap_involved: false | shares_owned_after: 2,847.00 | transaction_form_type: 4 | Footnotes: F4
    • Sold 2,847 shares of Stock Option (Right to Buy) at $7.57 per share (Derivative)
      Date: 2026-01-16 | Code: M | Expires: 2026-02-19 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4

    Footnotes:

    • F1: Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a preset sales plan adopted by the reporting person on November 12, 2025.
    • F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.26 to $13.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
    • F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.83 to $13.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
    • F4: This option is fully vested and exercisable. The option is due to expire on February 19, 2026.

Search

News categories